Kathryn L Chapman

发表

Does age matter? The impact of rodent age on study outcomes

J. Latcham, A. Rice, S. Jackson, 2016, Laboratory animals.

Working in partnership to advance the 3Rs in toxicity testing.

Stuart Creton, Kathryn Chapman, Anthony M Holmes, 2010, Toxicology.

Social housing of non-rodents during cardiovascular recordings in safety pharmacology and toxicology studies

Jean-Pierre Valentin, Helen Prior, Nick Edmunds, 2016, Journal of pharmacological and toxicological methods.

Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review.

Sally Robinson, Helen Palmer, E. Scott, 2011, Regulatory toxicology and pharmacology : RTP.

The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.

Jennifer Sims, Paul Baldrick, Kathryn L Chapman, 2012, Regulatory toxicology and pharmacology : RTP.

Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation.

Stuart Creton, Henry Holzgrefe, A. Hoberman, 2013, Regulatory toxicology and pharmacology : RTP.

Neuroscience and Biobehavioral Reviews the Predictive Validity of the Rat Self-administration Model for Abuse Liability

E. O'Connor, Kathryn L Chapman, P. Butler, 2022 .

The future of non-human primate use in mAb development.

Kathryn L Chapman, N. Pullen, I. Ragan, 2010, Drug discovery today.

Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials.

S. Jackson, Kathryn L Chapman, J. Valentin, 2016, Regulatory toxicology and pharmacology : RTP.

Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies

Nicholas M Katritsis, W. Hwang, F. Weber, 2020, bioRxiv.

Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.

Neil Spooner, Amanda Wilson, Sally Robinson, 2014, Drug discovery today.

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

T. Maclachlan, Kathryn L Chapman, J. W. van der Laan, 2017, mAbs.

Pharmacological validation of individual animal locomotion, temperature and behavioural analysis in group-housed rats using a novel automated home cage analysis system: A comparison with the modified Irwin test.

Rowland R. Sillito, J. D. Armstrong, N. Karp, 2018, Journal of pharmacological and toxicological methods.

Rodent big brother: Development and validation of a home cage automated behavioural monitoring system for use in repeat-dose toxicity studies in rats

J. D. Armstrong, T. Lukins, Kathryn L Chapman, 2014 .

Pioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs).

Fiona Sewell, Natalie Burden, Kathryn Chapman, 2015, Journal of the American Association for Laboratory Animal Science : JAALAS.

Current and prospective computational approaches and challenges for developing COVID-19 vaccines

Woochang Hwang, Kathryn Chapman, Namshik Han, 2021, Advanced Drug Delivery Reviews.

Automated recording of home cage activity and temperature of individual rats housed in social groups: The Rodent Big Brother project

Claire Grant, David J. Simpson, Natasha A Karp, 2017, PloS one.

Testing Chemical Safety: What Is Needed to Ensure the Widespread Application of Non-animal Approaches?

Fiona Sewell, Natalie Burden, Kathryn Chapman, 2015, PLoS biology.

Preclinical safety testing of monoclonal antibodies: the significance of species relevance

Kathryn L Chapman, N. Pullen, I. Ragan, 2007, Nature Reviews Drug Discovery.

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Fiona Sewell, Sally Robinson, Beatriz Silva Lima, 2014, Regulatory toxicology and pharmacology : RTP.

Reducing pre-clinical blood volumes for toxicokinetics: toxicologists, pathologists and bioanalysts unite.

Neil Spooner, Amanda Wilson, Sally Robinson, 2014, Bioanalysis.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

Sally Robinson, Kathryn Chapman, David Dreher, 2008, Regulatory toxicology and pharmacology : RTP.

Human clearance prediction: shifting the paradigm

Malcolm Rowland, Thierry Lavé, Kathryn Chapman, 2009, Expert opinion on drug metabolism & toxicology.

The value of acute toxicity studies to support the clinical management of overdose and poisoning: a cross-discipline consensus.

Martin F. Wilks, Stuart Creton, Kathryn Chapman, 2010, Regulatory toxicology and pharmacology : RTP.

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies

W. Hwang, F. Weber, T. Kouzarides, 2021, Science Advances.

Challenging the regulatory requirement for conventional acute toxicity studies in pharmaceutical drug development

David Dreher, Kathryn L Chapman, S. Robinson, 2007 .

Preclinical development of monoclonal antibodies

Ian Ragan, Kathryn Chapman, Colin Green, 2009, mAbs.

Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges

Jennifer Sims, Ian Ragan, Kathryn Chapman, 2016, mAbs.

A global pharmaceutical company initiative: an evidence-based approach to define the upper limit of body weight loss in short term toxicity studies.

Fiona Sewell, Sally Robinson, Kathryn Chapman, 2013, Regulatory toxicology and pharmacology : RTP.

Opportunities for Implementing the 3 Rs in Drug Development and Safety Assessment Studies Using Nonhuman Primates

Wolfgang Müller, Kathryn Bayne, Mark Prescott, 2015 .

Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review.

E. Scott, Kathryn L Chapman, S. Robinson, 2011, Regulatory toxicology and pharmacology : RTP.

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

David Dreher, Kathryn L Chapman, M. Festag, 2008, Regulatory toxicology and pharmacology : RTP.

Are acute toxicity studies required to support overdose for new medicines?

Kathryn L Chapman, S. Robinson, 2009, Regulatory toxicology and pharmacology : RTP.

The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.

Kathryn L Chapman, N. Pullen, C. Bowman, 2012, Regulatory toxicology and pharmacology : RTP.

Reducing pre-clinical blood volumes for toxicokinetics: toxicologists, pathologists and bioanalysts unite.

Kathryn L Chapman, Amanda Wilson, N. Spooner, 2014, Bioanalysis.

Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.

Kathryn L Chapman, Amanda Wilson, N. Spooner, 2014, Drug discovery today.